High Court Won't Mull Punitives In Drug Labeling Suits

Law360, New York (October 7, 2013, 6:49 PM EDT) -- The U.S. Supreme Court declined Monday to consider Novartis Pharmaceutical Corp.'s contention that federal law preempts the awarding of punitive damages for the legal marketing of prescription drugs, keeping in place a $1.2 million verdict against the drugmaker.

Novartis argued in a petition for writ of certiorari filed in May that the Fourth Circuit never should have upheld a verdict in favor of plaintiff Herbert Fussman, whose late wife, Rita, was allegedly disfigured by Novartis' bone drugs Aredia and Zometa. State punitive damage awards encroach on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.